

## Product Data Sheet

Product Name: SLC6A19-IN-4

Cat. No.: GC81444

### Chemical Properties

Cas. No. 2962069-39-0


Formula  $C_{16}H_{16}F_3N_3O_3$  M.Wt 355.31

Solubility DMSO: 50 mg/mL (140.72 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



### Background

SLC6A19-IN-4 is an allosteric-competitive and orally active B<sub>0</sub> AT<sub>1</sub> inhibitor. SLC6A19-IN-4 inhibits both human and mouse B<sub>0</sub> AT<sub>1</sub> with IC<sub>50</sub> values of 513 nM and 295 nM, respectively. SLC6A19-IN-4 exhibits excellent metabolic stability. SLC6A19-IN-4 significantly increases urinary phenylalanine

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

## Product Data Sheet

---

(Phe) excretion and reduces plasma Phe levels through dual inhibition of B 0 AT1 in both the intestine (reducing absorption) and kidney (promoting excretion) in vivo. SLC6A19-IN-4 can be used for phenylketonuria (PKU) and other disorders involving SLC6 -family transporters research [1].

In Vivo, SLC6A19-IN-4 (30 mg/kg, p.o., once) reduces intestinal Phe absorption promotes urinary excretion and lowers systemic Phe levels in male Pahenu2 mice carry a homozygous F263[1].

In Vitro, SLC6A19-IN-4 (1500-4000 nM) increases the Km for d5-Phe without affecting Vmax, indicating competitive inhibition (Km = 0.866, 5.19, 12.1 mM Vmax = 337, 351, 380  $\mu$ mol/min/mg-protein) in the Jump-In TI platform cells expressing human SLC6A19 and human Collectrin[1]. SLC6A19-IN-4 revealed Kd = 123.1 nM for mock cell and mB0AT1 and ACE2-expressing cell and Kd = 46.98 nM in mock cell and hB0AT1 and ACE2-expressing cell[1].

### References:

[1]. Takuya Imazu, et al., Structure-guided development of a potent human B0AT1 inhibitor effective in a mouse model of phenylketonuria. bioRxiv. 2025.10.27.684712

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA